Altmann Annette, Kissel Maria, Zitzmann Sabine, Kübler Wolfgang, Mahmut Miriam, Peschke Peter, Haberkorn Uwe
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany.
J Nucl Med. 2003 Jun;44(6):973-80.
The transport of MIBG by the human norepinephrine transporter (hNET) seems to be the critical step in the treatment of MIBG-concentrating tumors. Therefore, we investigated whether the accumulation of MIBG may be induced by retroviral transfection of the hNET gene in Morris hepatoma cells.
A bicistronic retroviral vector for the transfer of the hNET coding sequence and the hygromycin resistance gene was generated. Morris hepatoma cells (MH3924A) were infected with the respective retroviral particles, and hNET-expressing cell lines MHhNEThyg1 to MHhNEThyg9 were obtained through hygromycin selection. The uptake of (3)H-norepinephrine or (131)I-MIBG and the efflux of (131)I-MIBG were determined in transfected and wild-type cells. In addition, the (131)I-MIBG distribution was monitored in nude mice and rats bearing wild-type and hNET-expressing hepatomas.
hNET-expressing hepatoma cell lines accumulated up to 36 times more norepinephrine than did wild-type cells and 8 times more than did hNET-expressing neuroblastoma cell line SK-N-SH. The addition of nisoxetine, a selective inhibitor of noradrenaline uptake, inhibited norepinephrine uptake. Maximal (131)I-MIBG accumulation was observed 2 h after incubation and was followed by 43% efflux within 4 h after the (131)I-MIBG-containing medium had been removed. In vivo experiments performed with nude mice bearing both hNET-expressing and wild-type tumors showed a 10-fold-higher accumulation of (131)I-MIBG in transfected tumors than in wild-type tumors. The ex vivo calculations revealed doses of 605 and 75 mGy in hNET-expressing and wild-type tumor tissues, respectively.
Transduction of the hNET gene enables Morris hepatoma cells to accumulate norepinephrine and MIBG. However, the retention of MIBG is brief; therefore, the absorbed dose of radiation in vivo is not expected to be therapeutically effective.
人去甲肾上腺素转运体(hNET)对间碘苄胍(MIBG)的转运似乎是治疗摄取MIBG肿瘤的关键步骤。因此,我们研究了在Morris肝癌细胞中通过逆转录病毒转染hNET基因是否可诱导MIBG的蓄积。
构建了一种用于转移hNET编码序列和潮霉素抗性基因的双顺反子逆转录病毒载体。用相应的逆转录病毒颗粒感染Morris肝癌细胞(MH3924A),通过潮霉素筛选获得表达hNET的细胞系MHhNEThyg1至MHhNEThyg9。在转染细胞和野生型细胞中测定³H-去甲肾上腺素或¹³¹I-MIBG的摄取以及¹³¹I-MIBG的流出。此外,在荷野生型和表达hNET肝癌的裸鼠和大鼠中监测¹³¹I-MIBG的分布。
表达hNET的肝癌细胞系去甲肾上腺素蓄积量比野生型细胞多高达36倍,比表达hNET的神经母细胞瘤细胞系SK-N-SH多8倍。加入去甲肾上腺素摄取的选择性抑制剂尼索西汀可抑制去甲肾上腺素摄取。孵育2小时后观察到¹³¹I-MIBG蓄积量最大,在去除含¹³¹I-MIBG的培养基后4小时内随后有43%的流出。对荷表达hNET和野生型肿瘤的裸鼠进行的体内实验显示,转染肿瘤中¹³¹I-MIBG的蓄积量比野生型肿瘤高10倍。离体计算显示,表达hNET和野生型肿瘤组织中的剂量分别为605和75毫戈瑞。
hNET基因的转导使Morris肝癌细胞能够蓄积去甲肾上腺素和MIBG。然而,MIBG的保留时间短暂;因此,体内吸收的辐射剂量预计无治疗效果。